29/07/2026
A strong start to FY27 with sustained growth and strategic expansion.
Epigral reported ₹709 Crore in revenue for Q1FY27, reflecting 15% YoY growth, while PAT increased by 25% to ₹99 Crore and EBITDA reached ₹179 Crore, showcasing the strength of our integrated operations and diversified product portfolio.
Further strengthening our long-term growth roadmap, the Board has approved a ₹600 Crore capex to establish an Epoxy Resin & Formulations plant and a Multi-Purpose Plant (MPP), expanding our presence in advanced materials and specialty chemicals.
Together, these milestones reinforce Epigral's commitment to sustainable growth, strengthening Integration and creating long-term value for all stakeholders.
(Financial results, Quarterly results, Business growth, Chemical manufacturer)